Cobra Biologics Wins Innovation Grant

Cobra Biologics, the international clinical and commercial manufacturer of biologics and pharmaceuticals, with the University of Birmingham have been awarded a 3 year grant funded by the Biotechnology and Biological Sciences Research Council (BBSRC), Technology Strategy Board (TSB) and the Engineering and Physical Sciences Research Council (EPSRC) to develop innovative screening procedures for microbial expression systems and advanced fermentation processes for the production of novel therapeutic proteins.

The project will be led by Dr Tim Overton from the School of Chemical Engineering at the University of Birmingham, with input from Professor Jeff Cole from the School of Biosciences. The project builds on work performed at Birmingham funded by the BBSRC-EPSRC Bioprocess Research Industry Club (BRIC).

Peter Coleman CEO of Cobra Biologics said “Cobra is delighted to have been awarded this KTP grant with the University of Birmingham. Our customers expect us, as a Contract Manufacturing Organisation, to be able to provide cost effective and advanced production solutions in order for them to bring novel and ground breaking drugs to patients. We look forward to working with Dr Tim Overton and Prof Jeff Cole in continuing to develop our long term collaborations with the University of Birmingham into the field of microbial protein production”.